Human Genome Sciences says the final data from its mid-stage trial of Albuferon for hepatitis C were positive. The Phase IIb trial combined Albuferon with ribavirin against genotype 1 chronic hepatitis C. HGS says the data confirm that Albuferon is at least as effective as peginterferon alfa-2a while requiring half of the injections. The Rockville, MD-based developer says it will make a full presentation on the data later this year.
- see this release for more
- read the AP report on the trial
Related Articles:
Novartis inks major licensing pact with HGS. Report
HGS adds positive data in extended lupus trial. Report
HGS signs $425M deal for BioMed Realty campus. Report
Feds ink HGS contract. Report